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Background: Interstitial brachytherapy (ISBT) is an optional treatment for locally advanced gynecological tumours
for which conventional intracavitary brachytherapy (ICBT) would result in suboptimal dose coverage. However, ISBT
with Martinez Universal Perineal Interstitial Template (MUPIT), in which ~10-20 needles are usually applied, is more
time-consuming and labor-intensive than ICBT alone, making it a burden on both practitioners and patients.
Therefore, here we investigated the applicability of a combined intracavitary/interstitial (IC/IS) approach in
image-guided adaptive brachytherapy for bulky and/or irregularly shaped gynecological tumours for which
interstitial brachytherapy (ISBT) was performed.
Methods: Twenty-one consecutive patients with gynecological malignancies treated with computed tomography-guided
ISBT using MUPIT were analyzed as cases for this dosimetric study. For each patient, the IC/IS plan using a tandem and
1 or 2 interstitial needles, which was modeled after the combined IC/IS approach, was generated and compared with
the IS plan based on the clinical ISBT plan, while the IC plan using only the tandem was applied as a simplified control.
Maximal dose was prescribed to the high-risk clinical target volume (HR-CTV) while keeping the dose constraints of D2cc
bladder < 7.0 Gy and D2cc rectum < 6.0 Gy. The plan with D90 HR-CTV exceeding 6.0 Gy was considered acceptable.
Results: The average D90 HR-CTV was 77%, 118% and 140% in the IC, IC/IS and IS plans, respectively, where 6 Gy
corresponds to 100%. The average of the ratio of D90 HR-CTV to D2cc rectum (gain factor (GF) rectum) in the IC,
IC/IS and IS plans was 0.8, 1.3 and 1.5 respectively, while GFbladder was 0.9, 1.4 and 1.6, respectively. In the IC/IS plan,
D90 HR-CTV, GFrectum and GFbladder exceeded 100%, 1.0 and 1.0, respectively, in all patients.
Conclusions: These data demonstrated that the combined IC/IS approach could be a viable alternative to ISBT for
gynecological malignancies with bulky and/or irregularly shaped tumours.* Correspondence: oiketakahiro@gmail.com
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Interstitial brachytherapy (ISBT) is a choice of curative
treatment for locally advanced gynecological tumours
with extension to the lateral parametria and/or lower va-
ginal wall, for which intracavitary brachytherapy (ICBT)
would result in suboptimal dose coverage [1]. Accordingly,
we have been treating patients with locally advanced cer-
vical tumours and other gynecological malignancies using
in-room and in-situ computed tomography (CT)-guided
adaptive high dose rate (HDR) ISBT with Martinez Uni-
versal Perineal Interstitial Template (MUPIT, Nucleotron)
[2]. However, ISBT with MUPIT, in which ~10-20 needles
are usually applied, is more time-consuming and labor-
intensive than ICBT alone, making it a burden on practi-
tioners. Moreover, patients receiving this treatment also
must bear the hardship of keeping interstitial needles im-
planted for several days. Besides, facilities at which ISBT is
routinely performed are limited in Japan [3]. These aspects
have prompted us to explore alternative treatment strat-
egies for bulky and/or irregularly shaped tumours.
The recent development of technologies in image-
guided adaptive brachytherapy (IGABT) has enabled the
integration of magnetic resonance imaging (MRI) or CT
images into the treatment planning process [4-6]. This
has resulted in the adaptive target concept, with dose
volume assessment balancing constraints for the clinical
target volume (CTV) and organs at risk (OARs). In
2011, Pötter et al. reported the long-term results of 156
cervical cancer patients treated with chemoradiotherapy,
demonstrating an overall 3-year local control rate of
92% for locally advanced tumours (>5 cm) treated with
the MRI-guided combined intracavitary/interstitial (IC/
IS) approach [7]. This indicates that the image-guided
combined IC/IS approach with a few interstitial needles
could be a viable alternative to ISBT with MUPIT in the
treatment of bulky and/or irregularly shaped tumours.
Therefore, here we performed a dosimetric study to ex-
plore the applicability of the CT-guided combined IC/IS
approach in patients with gynecological malignancies
with bulky and/or irregularly shaped tumours, who were
actually treated with CT-guided ISBT with MUPIT.
Methods
Twenty-one consecutive patients with gynecological
malignancies treated with CT-guided adaptive HDR
ISBT with MUPIT using iridium-192 source at Gunma
University Hospital between April 2008 and February
2013 were selected by IRB-approved retrospective chart
review. Fourteen of them (67%) were cervical cancer pa-
tients. The rest included vaginal cancer (3 patients),
uterine endometrioid cancer (3 patients) and ovarian
cancer (1 patient). Among them, 10/14, 1/3, 3/3 and 1/1
patients with cervical, vaginal, uterine endometrioid
and ovarian cancer had recurrent tumours. Althoughthese cases were heterogeneous in terms of primary
tumour site and whether they were primary diseases or
recurrences, they had the commonality of developing
bulky and/or irregularly shaped tumours in the uterine
cervix or vaginal stump and/or parametrium. Hence,
they were considered to be favorable hypothetical cases
of locally advanced cervical cancer, which has the indi-
cation for the IC/IS approach in the clinic. For example,
a recurrent ovarian cancer case showed an intrapelvic
tumour with bilateral parametrial involvement predom-
inantly in the right side (Additional file 1: Figure S1).
Average ± standard deviation (SD) of high-risk CTV
(HR-CTV) in the present study was 60 ± 32 cm3, which
was similar to the values of patients with locally ad-
vanced cervical cancer treated with combined IC/IS by
the Utrecht group (66 ± 34 cm3) [8]. Moreover, in our
study, the distance between the tandem and the outer
contour of HR-CTV was 30 mm or greater in all cases.
The Utrecht group employed a distance of 30 mm as
cutoff value for adding interstitial needles to the usual
applicator consisting of the tandem and ovoids in
IGABT for locally advanced cervical cancer [9]. Accord-
ingly, the Vienna group reported that a distance of
25 mm in the plane of point A and that of 35 mm at
ring level could be covered by sufficient dose using only
the intracavitary part of the Vienna applicator [10]. To-
gether, these data suggest that the cases selected in the
current study were typical of extended tumours for
which ISBT is recommended.
Application of the tandem, an endovaginal cylinder with
MUPIT and interstitial needles was performed under in-
room and in-situ CT guidance. Detailed procedure of the
actually performed ISBT was previously described [2]. Tar-
get delineation was performed on CT images taken by an
in-room CT scanner with reference to MRI images taken
just before brachytherapy. The contours of HR-CTV, rec-
tum and bladder were delineated according to the GEC-
ESTRO recommendations [4].
We aimed to assess the applicability of a plan using
the tandem and a few interstitial needles (IC/IS plan) as
a viable alternative to the actually performed ISBT plan
using MUPIT (IS plan). For this purpose, the IC/IS plan
was generated on the CT image used for the actual ISBT
treatments in each patient using the PLATO Brachyther-
apy Planning System (ver.14.3.6, Nucletron) or Oncentra
(ver.4, Nucletron). For the IC/IS plan, the number of
interstitial needles used for source loading was set at 1
or 2, taking the burden of needle application for the
practitioners into consideration. Interstitial needles lo-
cated at the edge of the extended part of HR-CTV were
selected from needles implanted with MUPIT (9–18
needles; median, 14) based on visual inspection. One
needle was used in 17 cases with unilaterally extended
tumours, while 2 needles were selected in 4 cases with
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laterodorsal positions were most frequently selected
(Figure 1), consistent with a previous report showing
95% of locally advanced cervical cancer cases treated
with the Utrecht applicator received needle implant-
ation in laterodorsal positions [8]. This suggests the au-
thenticity of the positions of the needles selected in the
current study as those used for the combined IC/IS ap-
proach. The IC plans, with only the tandem used for
source loading, were generated as simplified controls
since treatment plans with ovoids or a ring applicator
with a tandem have large diversity in the spatial dispos-
ition of the applicators.
In the treatment planning for each of the IC, IC/IS
and IS plans, the highest possible dose was prescribed to
HR-CTV while keeping the dose constraints for rectum
and bladder. Comparison of dose volume parameters for
HR-CTV between the plans while keeping the same dose
constraints for the OARs helps clarify the dosimetric
gain of the plans. We have previously investigated late
rectal complications in cervical cancer patients treated
with EBRT plus ICBT, showing that the average total
EQD2 (α/β = 3.0) for D2cc rectum in cases with late rec-
tal complications and those without was 69 and 57 Gy,
respectively. Based on these findings, here we set the
dose constraint for rectum at D2cc < 6 Gy, which results
in total EQD2 of 59 Gy when the Japanese standard
treatment regimen for advanced cervical cancer (30 Gy/15
fractions of whole pelvic irradiation followed by 20 Gy/10
fractions of EBRT with midline block and 4 sessions of
ICBT) was employed [11]. There has been no concrete
evidence so far regarding the dose constraint for bladder
using the Japanese treatment regimen. However, severalFigure 1 Frequency of interstitial needles used in the IC/IS plan
per needle location. Relative locations of the needles to the
tandem in a transverse plane were plotted in steps of 30 degrees.
Twenty-five needles in 21 patients were used.European groups have revealed that the tolerability of
bladder to radiotherapy is relatively higher than that of
rectum [7,8]. In reference to their data, we set the dose
constraint for bladder at D2cc < 7 Gy.
D90, the most significant dose volume parameter for
local control in IGABT for cervical cancer [12], was used
to assess HR-CTV coverage. We previously reported
DVH analysis of ICBT for cervical cancer, in which CT
images taken just before ICBT were superimposed on
the 3-dimensional treatment plan of ICBT [13]. The
study demonstrated that ′tumour volumes′ almost cor-
responding to the current HR-CTV in GEC-ESTRO rec-
ommendations [5] receiving less than a total of 24 Gy in
4 fractions were significantly larger in patients with local
recurrence than in those with local control. Based on
these data, here, a plan showing D90 HR-CTV higher
than 6 Gy while keeping the dose constraints for the
OARs was considered acceptable.
To clearly understand the dosimetric gain of a plan, gain
factor (GF) was defined as the ratio of D90 HR-CTV to
D2cc of rectum and bladder, respectively: GFrectum = D90
HR-CTV/D2cc rectum, GFbladder = (D90 HR-CTV/D2cc
bladder) × 7/6. In the present study, 6 Gy for D2cc rectum
and 7 Gy for D2cc bladder were employed as dose con-
straints, and the plan showing D90 HR-CTV higher than
6 Gy while keeping these dose constraints was considered
acceptable. Hence, with regard to rectum, GFrectum of a
″borderline-acceptable″ plan showing D90 HR-CTV of
6 Gy and D2cc rectum of 6 Gy becomes 1.0, favorably.
However, in the case of bladder, GFbladder of a ″border-
line-acceptable″ plan showing D90 HR-CTV of 6 Gy and
D2cc bladder of 7 Gy becomes 0.86 (i.e., 6/7). In order to
make this value 1.0, the coefficient ″7/6″ was used in cal-
culating GFbladder. Together, a GF higher than 1.0 indicates
that the plan has the potential of being definitive and ac-
ceptable in terms of late toxicities for rectum or bladder.
The treatment plans were confirmed by two radiation on-
cologists (T. Oike and T. Ohno).
D98 and V6Gy of HR-CTV were also analyzed for target
coverage, while V12Gy HR-CTV was examined for high
dose volume [5]. For inter-comparison of plans with dif-
ferent dose prescriptions, V6Gy and V12Gy, the volumes re-
ceiving at least 6 and 12 Gy, were selected as alternatives
for V100 and V200, respectively. Differences in DVH pa-
rameters were evaluated for significance by paired t-test
using StatMateIII (ver. 3.17, ATMS). A P value < 0.05 was
considered significant.
Of note, in the present study, the cases were analyzed
simply as samples for dosimetric comparison of the treat-
ment plans to test the applicability of the combined IC/IS
approach for bulky and/or irregularly shaped tumours.
Thus, here we do not aim to discuss the curability of
these cases in light of the actually performed treatments.
Accordingly, the clinical information, including treatment
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Results and discussion
The IC plans with only the tandem resulted in insufficient
HR-CTV coverage as expected (Figure 2a-e, Figure 3a,
Table 1). D90 HR-CTV was below 100% (i.e., 6.0 Gy) in
81% (17/21). GFrectum and GFbladder were below 1.0 in 81%
(17/21) and 52% (11/21), respectively. Interestingly, the
addition of one or two needles to the IC plan (i.e., the
IC/IS plan) dramatically improved the HR-CTV coverage
(Figure 2a-e, Figure 3b, Table 1). The D90 HR-CTV,
GFrectum, GFbladder, D98 HR-CTV and V6Gy HR-CTV of
the IC/IS plan was significantly higher than that of the IC
plan (P < 0.001 in all parameters). Of note, D90 HR-CTV,
GFrectum and GFbladder exceeded 100% (i.e., 6.0 Gy), 1.0
and 1.0, respectively, in all cases. These data indicate that
the combined IC/IS approach can achieve satisfactory
dose distribution with acceptable HR-CTV coverage and
tolerable sparing of rectum and bladder in bulky and/or ir-
regularly shaped tumours for which ISBT was performed.
In our IC/IS model with a few needles, the reprodu-
cible placement of needles to the most appropriate posi-
tions of HR-CTV is required to achieve favorable doseFigure 2 DVH parameters in the IC, IC/IS and IS plans in all patients. (
CTV, (f) V12Gy HR-CTV. D90 and D98 HR-CTV were described in “%”, where 6distribution. For this purpose, the Vienna (I) and Utrecht
applicators dedicated to the combined IC/IS approach
would become effective tools [10,14], although the lat-
eral dimensions of the extended isodose lines are limited
after adding needles. Furthermore, exploration to iden-
tify the optimal treatment plan (i.e., optimal number and
position of needles) for balancing satisfactory dose distri-
butions and clinical burden should be conducted in the
near future.
Our data and those of others indicate that needles in
laterodorsal positions are most frequently used for
source loading in the combined IC/IS approach (Figure 1)
[8]. Meanwhile, laterodorsal contours of HR-CTV tend
to be overestimated by CT compared with MRI, which
is a major advantage of MRI in discrimination of tu-
mours and adjacent normal tissue [5,15]. In this regard,
it can be said that our study has a limitation in compar-
ing the target coverage in the laterodorsal directions
between ISBT with MUPIT and the combined IC/IS
approach. Thus, an analysis in the same way as the
present study and using MRI-based treatment plans
should be carried out. Thus, to validate our results
of the MRI-guided combined IC/IS approach, we are
preparing to introduce a treatment planning system ina) D90 HR-CTV, (b) GFrectum, (c) GFbladder, (d) D98 HR-CTV, (e) V6Gy HR-
Gy corresponds to 100%. NS, not statistically significant.
Figure 3 Representative dose distributions in transverse planes (a-c) and DVH curves (d-f) provided by the IC plan (a, d), the IC/IS plan
with 1 needle (b, e), and the IS plan (c, f). The case is a 55-year-old patient with newly diagnosed cervical cancer, FIGO stage IIIB, treated with
concurrent chemoradiotherapy using weekly cisplatin. (a) Source loading via only the tandem shows insufficient coverage of HR-CTV (D90, 4.6
Gy; D98, 2.9 Gy; V6Gy, 81%). (b) Addition of source loading via 1 needle (arrow) in expanded tumour in the left laterodorsal direction improved
HR-CTV coverage (D90, 6.3 Gy; D98, 5.1 Gy; V6Gy, 93%). (c) Usage of the tandem and all 12 needles for source loading further improved HR-CTV
coverage (D90, 7.6 Gy; D98, 6.5 Gy; V6Gy, 100%).
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images, which should further improve the identification
of HR-CTV.
The IS plans achieved more conformal coverage
of HR-CTV than the IC/IS plans, leading to further
improvement of HR-CTV coverage and GFs compared
to the IC/IS plans (Figure 2a-e, Figure 3c, Table 1). The
D90 HR-CTV, GFrectum, GFbladder, D98 HR-CTV and
V6Gy HR-CTV values of the IS plan were significantly
higher than those of the IC/IS plan (P < 0.01, P < 0.01,Table 1 DVH parameters in IC, IC/IS and IS plans
HR-CTV
D90 (%) D98 (%) V6Gy (
IC plan 77 (20) 53 (15) 77 (14)
IC/IS plan 118 (22) 97 (18) 95 (3.5)
IS plan 140 (25) 115 (25) 98 (2.1)
Averages (SD) are shown.P < 0.05, P < 0.01 and P < 0.001, respectively). In fact, a
previous study has pointed out the existence of cases
with extremely bulky and/or irregularly shaped tumours
in which even the combined IC/IS approach resulted
in insufficient coverage for HR-CTV [8]. Together, ISBT
with MUPIT can still be advantageous for such cases.
The number and geometrical distribution of interstitial
needles affect the conformality of HR-CTV coverage.
Therefore, the conformality of HR-CTV coverage is of
particularly high importance in the combined IC/ISGain factor
%) V12Gy (%) Rectum Bladder
39 (12) 0.8 (0.2) 0.9 (0.2)
45 (16) 1.3 (0.3) 1.4 (0.3)
50 (21) 1.5 (0.3) 1.6 (0.3)
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eral indices such as the conformality index (COIN) to
evaluate the conformality of target coverage in brachy-
therapy have been proposed [16]. Interestingly, in the
setting of the current study where maximal dose was
prescribed to HR-CTV while keeping the dose con-
straint for the rectum (6 Gy) and bladder (7 Gy), COIN
becomes identical to V6Gy HR-CTV. As shown in
Figure 2e, V6Gy HR-CTV in the IC/IS plans has been
dramatically improved compared to that in the IC plans,
nearing that in the IC/IS plans. These data indicate that
the IC/IS approach improves its conformality compared
with the IC approach, and is close to ISBT in terms of
the conformality of HR-CTV coverage in bulky and/or
irregularly shaped gynecological tumours.
On the other hand, there was no significant difference
in V12Gy among the three plans (Figure 2f, Table 1). Al-
though V150 and V200 are recommended as DVH pa-
rameters for the high dose volume by GEC-ESTRO [11],
the clinical significance of the high dose volume has not
been elucidated by various IGABT techniques, which
certainly warrants further investigation.
The present study has limitations. First, the study de-
sign of employing ICBT with a tandem alone as a con-
trol is weak and is not suitable for clinical use in locally
advanced gynecological tumours. However, there are
many types of applicators for ICBT used in combination
with a tandem, including ovoids and a ring applicator. In
treatment planning using these applicators, large num-
bers of variables such as three-dimensional spatial dis-
position of the applicators and dwell time setting make
it difficult to standardize the scheme for optimization of
a control ICBT plan among patients, leading to the diffi-
culty of evaluating the pure dosimetric gain of additional
needles. Furthermore, dosimetric study comparing a
combined IC/IS technique using tandem, ovoids and a
few interstitial needles with ISBT in the same patient is
almost impossible because ovoids are not usually used in
ISBT in the clinic. Thus, if we aim to perform such dosi-
metric study, comparison of the two methods using dif-
ferent patients with different anatomical characteristics
in terms of tumours and OARs is inevitable. Such a
study design also results in a weak conclusion. Upon
taking these issues into consideration, in the present
study, we employed the IC plan with only a tandem as a
control. The optimal number and spatial disposition of
needles in combination with a tandem and other appli-
cators including ovoids should be further investigated.
Second, the present study was carried out based on the
assumption that the anatomy among the IC, the IC/IS
and the IS approach remains the same. However, in the
clinical setting, the anatomy, in particular the 3D-
configuration of HR-CTV, can be different among the
three methods according to the number and distributionof inserted needles. This issue should be carefully con-
sidered in the clinical application of the combined IC/IS
approach as an alternative to ISBT with MUPIT.
Conclusions
Here we have demonstrated a treatment plan consisting
of a tandem and at most 2 needles, which is a simplified
model for the combined IC/IS approach, achieving our
dose prescription criteria (i.e., D90 HR-CTV > 6.0 Gy,
D2cc rectum < 6.0 Gy and D2cc bladder < 7.0 Gy per frac-
tion) in all 21 consecutive patients with gynecological
malignancies actually treated with CT-guided ISBT using
MUPIT. This indicates the potential of the combined
IC/IS approach as an alternative to ISBT with MUPIT
in CT-guided adaptive brachytherapy for bulky and/or
irregularly shaped gynecological tumours. Further re-
search to assess the clinical feasibility of the combined
IC/IS approach should be carried out with an optimal
number and spatial disposition of needles in combin-
ation with a tandem and ovoids, and also anatomical
change by the insertion of a tandem and needles should
be taken into consideration.
Additional file
Additional file 1: Figure S1. Representative CT image of an implant for
the recurrent ovarian cancer case. The tumour shows bilateral parametrial
involvement predominant in the right side. An intrauterine tandem and
11 interstitial needles (white dots) were applied.
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